Medications

Striverdi® Respimat®   

This product is manufactured by Boehringer Ingelheim (Canada) Ltd. using the ingredient olodaterol hydrochloride.

This product is inhaled into the lungs using the Respimat®.


play
Respimat®


Why is it prescribed?

Olodaterol is long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.


  • Striverdi® Respimat® cartridge contains either 60 puffs (equal to 30 doses of medicine) or 28 puffs (equal to 14 doses of medicine) after you prepare your inhaler for the first use. There is enough medicine for 30 days or 14 days when it is used as 2 puffs 1 time each day.
  • Never spray the medication toward the eyes
  • Before the inhaler is used for the first time, the cartridge must be inserted into the inhaler and then primed.
  • Prepare For First Time Use:
    • Step 1. With the yellow cap closed, press the safety catch while pulling off the clear base. Be careful not to touch the piercing element located inside thebottom of the clear base.
    • Step 2. Write the discard by date on the label of the inhaler. The discard by date is 3 months from the date the cartridge is inserted into the inhaler.
    • Step 3. Take the cartridge out of the box. Push the narrow end of the cartridge into the inhaler. The base of the cartridge will not sit flush with the inhaler. About 1/8 of an inch will remain visible when the cartridge is correctly inserted. The cartridge can be pushed against a firm surface to ensure that it is correctly inserted. Do not remove the cartridge once it has been inserted into the inhaler.
    • Step 4. Put the clear base back into place. Do not remove the clear base again. The inhaler should not be taken apart after you have inserted the cartridge and put the clear base back.
  • Prime For First Time Use:
  • The following steps are needed to fill the dosing system the first time you use it and will not affect the number of doses available. After preparation and initial priming, the inhaler will be able to deliver the labeled number of doses (30 or 14). Proper priming of the inhaler is important to make sure the correct amount of medicine is delivered.
    • Step 5. Hold the inhaler upright, with the yellow cap closed, to avoid accidental release of the dose. Turn the clear base in the direction of the black arrows on the label until it clicks (half a turn).
    • Step 6. Flip the yellow cap until it snaps fully open.
    • Step 7. Point the inhaler toward the ground (away from your face). Press the dose release button. Close the yellow cap. Repeat Steps 5, 6, and 7 until a spray is visible. Once the spray is visible, you must repeat Steps 5, 6, and 7 three more times to make sure the inhaler is prepared for use. The inhaler is now ready to use. These steps will not affect the number of doses available. After preparation and initial priming, the inhaler will be able to deliver the labeled number of doses (30 or 14).
  • Daily Dosing:
    • Step A. Hold the inhaler upright with the yellow cap closed, so you do not accidentally release a dose of medicine. Turn the clear base in the direction of the black arrows on the label until it clicks (half a turn).
    • Step B. Flip the yellow cap until it snaps fully open. Breathe out slowly and fully, and then close your lips around the end of the mouthpiece without covering the air vents. Point the inhaler to the back of your throat. While taking in a slow, deep breath through your mouth, press the dose release button and continue to breathe in slowly for as long as you can. Hold your breath for 10 seconds or for as long as comfortable. Repeat Step A and Step B so that you get the full dose. Close the yellow cap until you use the inhaler again.
  • Helpful Hints for Daily Dosing: If the inhaler has not been used for more than 3 days, spray 1 puff toward the ground to prepare the inhaler for use. If it has not been used for more than 21 days, repeat Steps 5, 6, and 7 until a spray is visible. Then repeat Steps 5, 6, and 7 three more times to prepare the inhaler for use.
  • The dose indicator shows approximately how much medicine is left. When the pointer enters the red area of the scale, there is enough medicine for 7 days (30 dose product) or 3 days (14 dose product). This is when you need to refill your prescription.
  • Once the dose indicator has reached the end of the scale, all puffs have been used and the inhaler locks automatically. At this point, the base cannot be turned any further.
  • Throw away the Striverdi® Respimat® inhaler 3 months after insertion of cartridge into inhaler, even if all the medicine has not been used, or when the inhaler is locked, whichever comes first.
  • Store at room temperature.

Alternatives

Other products that have the same ingredient as Striverdi® Respimat® are •Inspiolto® Respimat® •

See other products used in the treatment of •bronchitis •COPD •emphysema (COPD) •

The recommended adult dose is 2 puffs once daily, at the same time of the day.


Olodaterol is a long-acting beta2-agonist used as an inhalation for treating patients with chronic obstructive pulmonary disease (COPD). It relaxes the muscles in the breathing passages allowing for easier breathing and relief of symptoms such as shortness of breath and coughing.


The most commonly reported adverse reactions are:

  • cough
  • dizziness
  • headache
  • dry mouth
  • nausea
  • inflammation of the throat and nasal passages
  • symptoms of the common cold
  • nervousness, tremor
  • fatigue

Serious side effects that require immediate medical attention:

  • allergic reaction -  rash, hives, swelling of the face, lips, tongue or throat, difficulty swallowing or breathing
  • wheezing or coughing and difficulty breathing
  • chest pain, trouble breathing, swelling of the hands or feet, heartburn

  • Olodaterol is not indicated to treat acute deteriorations of COPD and is not indicated to treat asthma.
  • Long-acting beta2-adrenergic agonists (LABA), such as olodaterol, may increase the risk of asthma-related death. All LABA are contraindicated in patients with asthma without use of a long-term asthma control medication.
  • Olodaterol should not be started in patients with acutely deteriorating COPD, which may be a life threatening condition, or used as rescue therapy for acute episodes of bronchospasm. Acute symptoms should be treated with a relief (short-acting) inhaled medication.
  • Olodaterol should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medications containing long-acting beta2 agonists as an overdose may result. Cli
  • Olodaterol may produce paradoxical bronchospasm that may be life threatening. Stop using immediately if this occurs.
  • Use with caution in patients with
    • seizures
    • high blood pressure
    • heart problems such as fast or irregular heart beat
    • overactive thyroid
    • diabetes
  • This medication should not be used in children. It is not known if olodaterol is safe and effective in children.
  • The following may interact with olodaterol:
    • antidepressants, in particular tricyclic antidepressants and monoamine oxidase inhibitors (MAOIs)
    • medicines that decrease the level of potassium in your blood. These include diuretics (also known as water pills and are used to treat high blood pressure e.g. hydrochlorothiazide)
    • Other bronchodilators such as methylxanthines (e.g. theophylline)
    • steroids (e.g. prednisolone)
    • beta-blockers used in the treatment of high blood pressure or other heart problems (e.g. propranolol) or in the treatment of glaucoma (e.g. timolol)

Use in pregnancy and breastfeeding: Human data is lacking at this time.  Contact your doctor or pharmacist before using.


Page Last Updated: 05/10/2016